We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genomic Study Identifies Risk Regions for Intrahepatic Cholestasis of Pregnancy

By LabMedica International staff writers
Posted on 20 Jun 2026

Intrahepatic cholestasis of pregnancy (ICP) affects 0.2–2% of pregnancies and typically arises after 30 weeks, presenting with intense itching of the palms and soles. Diagnosis is confirmed by elevated liver enzymes and increased serum bile acids, and the condition is linked to higher risks of preterm birth and stillbirth. Although genetic susceptibility has been suspected, the underlying mechanisms have been unclear. New findings demonstrate that large-scale human genetic analyses have identified multiple regions associated with ICP.

Tampere University led an international genome-wide meta-analysis that combined genetic data from more than 4,700 women with a history of ICP and over 436,000 control women from Finland, Iceland, Estonia and Denmark. The study identified 26 genetic regions associated with ICP, including 10 not previously reported. Genes within these regions influence hepatic handling of bile acids, fats and cholesterol, aligning ICP susceptibility with broader disturbances in liver metabolism during pregnancy-related hormonal changes.


Image: Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that typically develops late in pregnancy, causing severe itching and increasing the risk of complications such as preterm birth and stillbirth (Image Credit: 123RF)
Image: Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that typically develops late in pregnancy, causing severe itching and increasing the risk of complications such as preterm birth and stillbirth (Image Credit: 123RF)

The investigators also examined clinical associations beyond pregnancy. Women with prior ICP showed an increased risk of hepatobiliary disorders, including fatty liver disease, gallstones and inflammation of the bile ducts, as well as higher rates of certain autoimmune diseases such as Crohn’s disease, thyroid disorders and type 2 diabetes. Analyses further suggested a possible shared genetic basis between ICP and pancreatitis.

The findings were published in Nature Communications on May 25, 2026. According to the study authors, the results hold promise for identifying at‑risk groups, improving diagnosis and treatment, and supporting the early identification of related conditions. The work involved researchers affiliated with Tampere University and the University of Oulu.

"Our analyses also suggested a possible shared genetic basis between ICP and pancreatitis, which is inflammation of the pancreas, meaning that the same genetic susceptibility may increase the risk of both conditions. This is a new discovery that, to our knowledge, has not been reported previously. However, further studies are needed to better understand this connection," said Jaakko Tyrmi, postdoctoral research fellow at Tampere University and the University of Oulu.

Related Links
Tampere University


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Automated Coagulation Analyzer
Hemolumi H6

Latest BioResearch News

New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
20 Jun 2026  |   BioResearch

Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
20 Jun 2026  |   BioResearch

Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
20 Jun 2026  |   BioResearch



ADLM